A $31.8 million cannabis-related verdict that a federal court wouldn’t enforce

A Michigan cannabis grower proved its case. A jury found that the buyer breached its supply agreement and awarded the grower $31.8 million in damages. But the grower still walked away without an enforceable verdict.

In Hello Farms Licensing MI, LLC v. GR Vending MI, LLC, the U.S. Court of Appeals for the Sixth Circuit reversed the judgment because the contract required the parties to engage in conduct prohibited by the federal Controlled Substances Act (“CSA”). The court held that a federal court could not enforce the agreement, despite Michigan law authorized the underlying cannabis activity.

The September 10, 2026, decision is not binding on California state courts or federal courts in the Ninth Circuit. Nevertheless, it offers an important warning for cannabis operators nationwide: A contract that is valid under state law may still be unenforceable in federal court.

The contract and breach

Hello Farms is a licensed Michigan cannabis cultivator. In November 2020, it entered into an output contract with GR Vending MI, LLC and CURA MI, LLC, both subsidiaries of Curaleaf Holdings, Inc. GR Vending agreed to purchase all cannabis grown by Hello Farms during its 2020 and 2021 harvests, while CURA MI guaranteed GR Vending’s obligations.

When the parties signed the agreement, Hello Farms held licenses to grow medical cannabis. GR Vending held both medical and adult-use retailer licenses.

The parties expected Hello Farms’ 2020 harvest to yield between 12,000 and 15,000 pounds of cannabis. GR Vending also agreed to pay a $2.2 million deposit, subject to refund under specified circumstances.

The agreement contained detailed testing requirements. Hello Farms had to test each 50-pound batch for THC potency and contaminants such as pesticides and heavy metals. Importantly, the contract required the marijuana to satisfy state and local recreational cannabis testing requirements.

Hello Farms ultimately produced approximately 16,300 pounds in 2020. The cannabis passed the required testing, and GR Vending accepted an initial shipment of roughly 2,000 pounds.

Then market prices fell.

GR Vending refused to accept additional deliveries. Hello Farms sold the remaining 2020 harvest to another buyer at lower prices. It also expanded its cultivation operation for 2021, obtained adult-use cultivation licenses, and sold that year’s production to the same alternative buyer.

From state court to federal court

Hello Farms sued for breach of contract in Michigan state court in February 2021. The defendants were able to move the case to the U.S. District Court for the Eastern District of Michigan based on diversity jurisdiction.

That procedural move would become critical.

The defendants asserted that the agreement was illegal under federal law and therefore unenforceable. The district court rejected that defense at summary judgment, and the case proceeded to trial.

The jury found that the defendants breached the contract and awarded Hello Farms $31.8 million. The defendants renewed their request for judgment as a matter of law, but the district court again rejected the federal-illegality defense.

The district court reasoned that the agreement concerned medical cannabis and that the Rohrabacher-Farr appropriations rider reflected a federal policy of tolerating state-compliant medical cannabis activity. The defendants appealed.

Why the verdict became unenforceable

The Sixth Circuit reversed.

As the court explained, federal courts generally apply state substantive law when exercising diversity jurisdiction. But the effect of illegality under a federal statute is a question of federal law. A federal court must therefore determine whether enforcing an agreement would enforce the precise conduct that Congress made unlawful.

That principle proved fatal to Hello Farms.

In the Court’s view, the agreement required Hello Farms to possess cannabis with the intent to distribute that cannabis to GR Vending and enable GR Vending to possess it for further distribution or sale. Each step implicated conduct prohibited by the CSA unless federally authorized.

The court distinguished between a lawful economic transaction that contains an incidental illegal provision and a contract whose central performance is itself federally prohibited. Hello Farms’ agreement fell into the second category because the purchase and distribution of cannabis were the core of the bargain.

The court consequently refused to enforce the defendants’ promise to pay for that performance. It reversed the district court’s denial of judgment as a matter of law, eliminating the prior verdict and Hello Farms’ recovery.

Money damages were no solution

Hello Farms argued that it was not asking the court to order anyone to grow, deliver, or purchase cannabis. The company sought money damages for a transaction that should have occurred years earlier.

The Sixth Circuit found that distinction unpersuasive.

Hello Farms’ lost profits arose from, and were measured by, the defendants’ promise to purchase cannabis. Awarding damages would therefore give Hello Farms the economic benefit it expected from the federally prohibited transaction.

According to the court, federal illegality is not limited to cases seeking specific performance. A court also may refuse to award expectation damages when the plaintiff’s claimed recovery depends on enforcement of the unlawful bargain itself.

This is one of the decision’s most significant lessons. Simply drafting a monetary remedy does not necessarily insulate a cannabis agreement from federal illegality. If the damages represent the profits expected from cannabis cultivation or sales, a federal court may conclude that awarding those damages would indirectly enforce the prohibited performance.

The opinion does not, however, resolve every potential claim involving a cannabis business. It does not hold that federal courts must reject every dispute involving consulting services, intellectual property, real estate, equipment, loans, restitution, or other obligations connected to the industry. The closer the claim is to direct cultivation, possession, purchase, or distribution, the greater the apparent risk under the Sixth Circuit’s reasoning.

Marijuana rescheduling didn’t save the contract

The fact the federal government moved state-legal medical marijuana to Schedule III earlier this year also failed to rescue Hello Farms’ verdict.

The Sixth Circuit explained that the federal change occurred years after the parties entered the contract. Nothing in the rescheduling rule made the change retroactive or transformed the parties’ 2020 agreement into a federally lawful transaction.

The court also noted that Schedule III does not eliminate federal regulatory requirements. State-licensed medical-cannabis businesses may still need DEA registration and applicable FDA approval to cultivate, distribute, or introduce cannabis products into interstate commerce lawfully.

Rescheduling therefore does not mean that every state-licensed cannabis transaction is now federally legal. Whether a particular agreement is enforceable may still depend on when it was executed, the products and markets it covers, the parties’ registrations, and the federal rules applicable to performance.

What California operators should do

The Sixth Circuit’s opinion is not controlling precedent in California or the Ninth Circuit. California courts may analyze contract illegality and public policy differently, and the enforceability of any agreement will depend on its terms, claims, remedy, and forum.

Still, the decision relies heavily on U.S. Supreme Court authority governing the power of federal courts to enforce federally prohibited agreements. California operators should not assume the risk stops at the Sixth Circuit’s boundaries.

The takeaway

Hello Farms convinced a jury that the defendants breached their agreement. It proved substantial damages and obtained a $31.8 million verdict. None of that was enough once the federal appellate court concluded that enforcing the verdict would enforce a federally illegal bargain.

The case does not establish that every cannabis-related agreement is unenforceable. But it does reinforce a basic reality that cannabis contracts must be drafted not only for commercial performance and state regulatory compliance, but also for the court or tribunal that may eventually be asked to enforce them.

In cannabis contracting, a strong damages provision matters, but only if the chosen forum is willing and legally able to enforce the underlying bargain.

_____________

For more updates on recent marijuana legislation, including rescheduling and the DEA rulemaking process, please check out these recent posts:

• What California Medical Operators Must Do After Rescheduling: DEA Registration, License Operation, and 280E
• The Quietest Fight of DEA’s Life: Reflections on the Marijuana Rescheduling Hearing
• Law and Politics: Why Marijuana Rescheduling’s One-Sided Hearing Matters
• Would Cannabis Rescheduling Help Businesses in Unified Markets? Washington Weighs In
• The Motion to Stay DEA’s Schedule III Rule: Strong Enough to Stick?
• Standing Is Everything: Three States Join the Medical Marijuana Rescheduling Fight
• Medical Marijuana Rescheduling Q&A: Cutting Through the Noise
• A Calculated Bet: DEA Registration is Open, and the Clock is Ticking
• Marijuana Rescheduling and Income Tax
• The U.S. Opens Its Medical Marijuana Market to Global Trade (For Now); Broader Marijuana Rescheduling on Deck

The post A $31.8 Million Cannabis-Related Verdict That a Federal Court Wouldn’t Enforce appeared first on Harris Sliwoski LLP.

from Canna Law Blog™ https://ift.tt/gUTWX3K
via IFTTT

Canna Country #26 in Southern Humboldt: The Ocimene Queen of Canna Country Farms

We head to Canna Country Farms in Humboldt for Legendary Strains to discover the Ocimene Queen herself, Canna Country #26.

The post Canna Country #26 in Southern Humboldt: The Ocimene Queen of Canna Country Farms appeared first on Leafly.

from Leafly https://ift.tt/ef2OmRI
via IFTTT

Jason Adelstone Moderates Federal Cannabis Policy Discussion at IgniteIt Denver

The federal conversation around hemp and cannabis is entering a pivotal new phase. On September 18 in Denver, Harris Sliwoski partner Jason Adelstone will moderate One Plant, One Policy, a fireside discussion at IgniteIt Denver Spotlight focused on the future of federal hemp regulation.

From cannabinoids and product standards to enforcement and consumer safety, policymakers are weighing how a single plant should be regulated in the years ahead. The decisions made at the federal level could significantly reshape the regulatory landscape for hemp and the businesses operating within it.

Jason will lead a discussion with Howard Lee, CEO of SōRSE Technology; Jordan Wellington, Managing Partner at Strategies 64; and Priyanka Sharma, Co-Founder and Co-CEO of Kazmira Therapeutics about the path toward a more coherent federal framework. The conversation will explore what meaningful reform could look like, where federal policy may be headed, and what a more unified approach could mean for the industry.

The panel will also consider the practical implications for operators. As federal policy evolves, businesses may face new compliance requirements and regulatory challenges, along with new opportunities. Understanding the direction of the conversation will be increasingly important for companies preparing for what comes next.

The post Jason Adelstone Moderates Federal Cannabis Policy Discussion at IgniteIt Denver appeared first on Harris Sliwoski LLP.

from Canna Law Blog™ https://ift.tt/dqM06aQ
via IFTTT

The 11 best weed pipes of 2026

The best weed pipes of 2026 are reviewed and tested by the Leafly Picks team of expert tokers to help you find the perfect pipe for you.

The post The 11 best weed pipes of 2026 appeared first on Leafly.

from Leafly https://ift.tt/6uxwAFy
via IFTTT

Medical Marijuana in Schedule III Survives Its First Major Challenge

On September 9th, the United States Court of Appeals for the District of Columbia denied a motion to stay filed by SAM, Inc. and the National Drug and Alcohol Screening Association, Inc. (collectively, “SAM”). The motion sought to stay (pause) the Attorney General’s final order placing state legal medical marijuana into Schedule III of the Controlled Substances Act (“CSA”). While this ruling merely maintains the status quo, it is still a significant victory for state legal medical marijuana operators.

This decision does not mean that medical marijuana will ultimately survive the litigation. What it does show, however, is that the Attorney General is likely to receive a fair hearing before the D.C. Circuit. Had the stay been granted, it would have been a devastating blow to the industry and almost certainly would have signaled defeat following a full hearing. The court’s decision, at least, suggests that it is taking the case seriously and considering the issues without prejudice.

Quick note on standing

Apparently, in an earlier blog post, I got the process backwards. I assumed the court would address standing first and then determine whether a stay was warranted. Instead, the court addressed the stay first, while standing will be addressed through the parties’ briefs.

Based on the court’s decision, this makes sense. Since the court denied the stay, there was no need to determine standing at this stage. Had the court granted the stay, standing likely would have needed to be addressed first and, given the outcome, presumably would have been established.

As I have discussed in several blog posts, but primarily in this one, I believe that standing is everything in this litigation. Despite the court’s denial of petitioners’ motion for a stay, I still believe that if petitioners are found to have standing, the Schedule III final order will ultimately be overturned. I hope I am wrong but based on a plain reading of 21 U.S.C. 811(d)(1) and some poor drafting in the final order, I do not see how the final order survives.

Motion to Intervene and Amicus Curiae

In its order, the court also denied the motion of two medical marijuana companies to intervene in the litigation. MedPharma Iowa, LLC and TriMountain Pure, LLC, through their attorney Shane Pennington, sought to intervene on the grounds that the Attorney General could not adequately represent the interests of businesses affected by the final order. They argued that medical marijuana operators should therefore have the opportunity to represent their own interests in the litigation.

The court ultimately denied the motion but is allowing the medical marijuana operators to participate as amici curiae. This is important because it will still allow the operators (i.e. Shane Pennington) to present their arguments for the court’s consideration.

The court also granted attorneys David Sergi, David Holland, Robert Hoban, and Tyson Daniel leave to participate as amici curiae.

What’s next in the litigation

The court set a 30-day deadline for the parties to submit proposed formats for briefing the cases. The court strongly urged SAM et al. (which includes SAM, the National Drug and Alcohol Screening Association, the states of Nebraska and Indiana, New Directions Addition Recovery Services, Elizabeth Stuyt, Cannabis Industry Victims Educating Litigators, MMJ International Inc., MJ BioPharma Cultivation Inc., MJ Biopharma Labs, Inc., and Kenneth Finn) to submit joint proposals, reminding the parties that “the court looks with extreme disfavor on repetitious submissions.”

The court further stated that it “will, where appropriate, require a joint brief of aligned parties with total words not to exceed the standard allotment for a single brief.” If Sam et al. believe separate briefs are necessary, they “must provide detailed justifications for any request to file separate briefs or to exceed in the aggregate the standard word allotment.”

After reviewing the parties’ proposed briefing formats, the court will set a briefing schedule. D.C. Circuit Rule 31 provides that SAM et al. must then file and serve their initial brief within 40 days. The Justice Department will then have 30 days to file its response brief. Finally, Sam et al. will then have 21 days to file and serve their reply brief.

Importantly, all of these timeframes remain subject to the court’s discretion. The court can expedite or extend the filing deadlines as it deems appropriate. Assuming no changes to these timelines and that the court issues a briefing schedule quickly, the timeline could look something like this.

1. October 9, 2026 – The parties submit their proposed briefing formats.
2. October 16, 2026 – The court issues its briefing schedule. This is, of course, an estimate since we do not know how long the court will take to issue the schedule.
3. November 25, 2026 – SAM et al.’s initial brief is due. (I checked, as of now the court is open on the day before Thanksgiving.)
4. December 24, 2026 – The Justice Department’s response brief is due. (The court currently appears to be open Christmas Eve, but closed last year on the 24. So, filing could be pushed to the 28th.)
5. January 14, 2027 – SAM et al.’s reply brief is due.

Typically, the final brief, which in this case would be SAM’s reply brief, will be due at least 45 days before oral argument. Assuming the timeline above, oral argument could occur around late February or early March 2027.

That means we may not know whether medical marijuana survives this challenge until at least March 2027. Assuming DEA sticks to its six-month goal for processing applications submitted during the early application period, those registrations could start being issued next month. Once DEA registrations are issued, the program becomes operational, making a reversal that much more disruptive. That is not to say the court would consider those practical consequences dispositive, but they are important realities.

What this means for state medical marijuana licensees

Because it appears the DEA registration program will become operational before the litigation concludes, licensed operators should be very careful about how they proceed and what language they include in their contracts. If the final order is overturned next year, any agreement involving interstate or international trade under the new framework may need to cease immediately upon the court issuing its order. If the final order survives, however, operators that begin operations quickly could secure a meaningful first mover advantage.

If you are an operator that submitted a DEA registration and would like guidance on how best to proceed, our international attorneys are here to help. Please do not hesitate to reach out for a free consultation.

For more on marijuana rescheduling and the DEA rulemaking process, please check out these recent posts:

• Medical Marijuana Schedule III Litigation: The D.C. Circuit's First Major Test
• The Quietest Fight of DEA’s Life: Reflections on the Marijuana Rescheduling Hearing
• Law and Politics: Why Marijuana Rescheduling’s One-Sided Hearing Matters
• Would Cannabis Rescheduling Help Businesses in Unified Markets? Washington Weighs In
• The Motion to Stay DEA’s Schedule III Rule: Strong Enough to Stick?
• Standing Is Everything: Three States Join the Medical Marijuana Rescheduling Fight
• Medical Marijuana Rescheduling Q&A: Cutting Through the Noise
• A Calculated Bet: DEA Registration is Open, and the Clock is Ticking
• Marijuana Rescheduling and Income Tax
• The U.S. Opens Its Medical Marijuana Market to Global Trade (For Now); Broader Marijuana Rescheduling on Deck

The post Medical Marijuana in Schedule III Survives Its First Major Challenge appeared first on Harris Sliwoski LLP.

from Canna Law Blog™ https://ift.tt/W2xg4Ri
via IFTTT

How to Acquire a Colorado Cannabis License

Colorado regulates marijuana businesses through the state Marijuana Enforcement Division (MED), while local jurisdictions retain separate licensing and regulatory authority over marijuana businesses within their boundaries. The current Colorado Marijuana Rules are codified at 1 CCR 212-3 (version effective January 5, 2026). Because state rules, forms, fee schedules, and local ordinances can change, applicants should confirm relevant requirements before filing or closing a transaction.

Who regulates marijuana licensing in Colorado?

The MED administers Colorado’s state marijuana licensing framework under the Colorado Marijuana Code and the Colorado Marijuana Rules. A regulated marijuana business may not operate until it has the state and local approvals or licenses required for its business and location. Colorado’s rules expressly condition state business licensing on relevant local approval. The also allow local jurisdictions to impose separate requirements concerning the time, place, and manner of marijuana businesses.

What types of marijuana business licenses are available?

Colorado maintains medical and retail marijuana business license categories that include stores, cultivation facilities, products manufacturers, testing facilities, transporters, and retail business operators. Colorado also recognizes a medical marijuana research and development facility license, and retail hospitality license types--including marijuana hospitality businesses and retail marijuana hospitality and sales businesses. In addition, Colorado’s licensing framework includes accelerator licenses associated with the social equity program. A separate state application is required for each license type.

Is Colorado accepting applications for new marijuana licenses?

Colorado law permits applications for regulated marijuana business licenses, but the availability of a particular license at a particular site depends in part on the local jurisdiction. Colorado rules allow a local jurisdiction to prohibit a regulated marijuana business license type, or to impose separate local licensing requirements. Accordingly, an applicant should confirm that the proposed jurisdiction and premises can support the intended license before making substantial site or transaction commitments.

What is the Colorado marijuana license application process?

The MED’s Regulated Marijuana Business License Application is Form DR 8548. As of July 1, 2026, applicants can now file a unified application for identical controlling beneficial owners who are applying for multiple licenses in the state.

The marijuana application requires disclosure information, a main application, authorization forms, and an affirmation of reasonable care, with additional addenda required for specified applicant structures or license types. The application materials address ownership and investment categories that include controlling beneficial owners and, where applicable, passive beneficial owners, qualified institutional investors, qualified private funds, and other interests addressed by Colorado law and MED rules.

The MED may require additional information or documents to process and investigate an application. Applicants may not operate the regulated marijuana business before obtaining all necessary state and local approvals or licenses.

What ownership and financial-interest categories does Colorado require applicants to understand?

Colorado does not treat every investor, lender, fund, or economic participant in a marijuana business the same. The Colorado Marijuana Rules divide ownership and financial interests into categories that determine what must be disclosed and, in some cases, who must be licensed or found suitable.

What is a Controlling Beneficial Owner (CBO)? A Controlling Beneficial Owner generally includes a person or entity that, acting alone or in concert, owns or acquires at least 10% of the owner’s interest in a regulated marijuana business; an affiliate that controls the business, including a manager; or another person or entity that is otherwise in a position to control the business. A Qualified Institutional Investor is generally treated as a CBO only when it owns or acquires more than 30% of the owner’s interest. CBO status is important because controlling beneficial owners are subject to the owner-licensing and disclosure framework in the MED rules.

What is a Passive Beneficial Owner (PBO)? A Passive Beneficial Owner is a person or entity that holds an ownership interest below the controlling-beneficial-owner threshold and is not otherwise in a position to control the regulated marijuana business. The rules distinguish passive ownership from control, but PBOs remain within the regulatory ownership framework and may be subject to disclosure or additional MED review, including reasonable-cause disclosure.

What is a Qualified Institutional Investor (QII)? A Qualified Institutional Investor is a specifically defined institutional investor, including certain regulated banks, bank holding companies, insurance companies, registered investment companies, employee benefit or pension plans, government pension plans, and qualifying groups of such institutions. The QII category matters because Colorado applies a different controlling-ownership threshold and disclosure treatment to qualifying institutional investors.

What is a Qualified Private Fund (QPF)? A Qualified Private Fund is generally a private investment fund that would be an investment company under the federal Investment Company Act of 1940 but for the exclusions in sections 3(c)(1) or 3(c)(7), is advised or managed by a properly registered investment adviser, and satisfies the additional requirements stated in the Colorado Marijuana Rules. When a QPF is a controlling beneficial owner, the MED requires organizational disclosure concerning persons who control the fund’s investment in, or management or operations of, the marijuana business.

What is an Indirect Financial Interest Holder (IFIH)? An Indirect Financial Interest Holder is a person with a financial or economic relationship to the regulated marijuana business who is not an affiliate, CBO, or PBO. The category can encompass specified debt, commercially reasonable royalties associated with intellectual property, and other economic arrangements recognized by the rules. Certain IFIHs receive heightened disclosure treatment, including a person who holds two or more indirect financial interests, is also a PBO, or provides previously undisclosed debt financing exceeding 50% of the business’s operating capital.

Why do these categories matter in an application or acquisition? The classification affects the scope of the MED’s disclosure, licensing, and suitability review. Colorado requires specified disclosures for controlling beneficial owners and certain indirect financial interest holders and authorizes additional disclosure of specified owners, affiliates, and financial interests. Applicants should therefore analyze not only the cap table, but also management and control rights, financing, royalties, fund structures, and other economic arrangements before filing or closing a change-of-ownership transaction.

What is a finding of suitability, and who may need one?

Colorado’s rules use findings of suitability as part of the licensing and ownership-review process for persons and entities that fall within specified ownership or investment categories. Controlling beneficial owners are subject to the owner-licensing requirements in the Colorado Marijuana Rules, and passive beneficial owners may elect or be required in specified circumstances to be subject to disclosure or licensure. Suitability and owner-license requirements therefore depend on the person’s or entity’s status under the current ownership provisions rather than on a single ownership-percentage rule applied to every investor.

What is required at the local level for Colorado marijuana licensing?

Local governments may impose licensing requirements separate from the MED’s state process. Those local requirements may address the proposed premises, zoning or land use, local application materials, inspections, hearings, and other locally imposed licensing conditions. In Denver, for example, the municipal code requires specified inspections and permits before issuance of a local marijuana license and requires a corresponding state license.

Do owners and employees need individual MED licenses or badges?

Colorado distinguishes Owner Licenses and Employee Licenses, and the rules provide for identification badges associated with those licenses. A natural person who is required by the rules to obtain an Employee License must obtain that license before beginning activities that require an Employee License. Controlling beneficial owners are subject to the Owner License provisions of the rules, while the required credential for any particular individual depends on that person’s ownership and operational role. The MED uses Form DR 8517 for the Marijuana Employee License Application.

How much does a Colorado marijuana business license cost?

Colorado does not impose one uniform state application-and-license fee across all regulated marijuana business license types. The current Colorado Marijuana Rules contain separate fee schedules by license category, and cultivation fees vary by tier or class. Under the current rules, the first payment is submitted with the application and the second payment is generally due at least twelve months before the license expiration date. Local jurisdictions may charge additional application, license, transfer, change-of-location, or other fees under local law.

How long are Colorado marijuana business licenses valid?

Senate Bill 24-076, which became law in 2024, extended initial state regulated-marijuana business license and renewal periods from one year to two years. The legislation permits local licensing authorities to determine whether local licenses are issued for one-year or two-year terms.

How long does the licensing process take?

The cited state materials do not establish a universal processing period for every new regulated marijuana business license. The application process requires state review, local approval, ownership and suitability review, payment of applicable fees, and satisfaction of premises-specific local requirements. A transaction timetable should therefore be based on the particular license type, ownership structure, premises, and local jurisdiction rather than on a single statewide processing estimate.

What special rules apply to new marijuana licenses in Denver?

Denver’s municipal code reserves applications for specified new marijuana business licenses to social equity applicants, subject to stated exceptions. The current Denver code provides that this social-equity exclusivity provision is repealed effective July 1, 2027. Denver separately imposes a moratorium on applications for new medical marijuana store and new medical marijuana cultivation facility licenses. Denver’s code also contains proximity, location, hearing, inspection, permit, and other local requirements that can affect whether a proposed premises is licensable.

Can a non-social-equity buyer acquire an existing Denver marijuana license before July 1, 2027?

Denver permits transfers of marijuana business ownership subject to approval by the local licensing authority and the requirements of its municipal code.

Before July 1, 2027, a license held by a social equity applicant may be transferred to social-equity or non-social-equity applicants only if at least fifty-one percent of the license remains held by one or more social equity applicants. A non-social equity applicant, however, may transfer its license to a non-social equity applicant without any additional social equity restrictions.

After July 1, 2027, Denver’s code states that licenses held by social equity applicants may be transferred to social-equity or non-social-equity applicants upon approval by the manager. A purchaser should therefore determine whether the target license is subject to Denver’s social-equity transfer restriction before structuring the acquisition.

Who qualifies as a Colorado social equity marijuana licensee?

The current Colorado Marijuana Rules implement the statutory social-equity framework and require applicants to establish qualification under the criteria applicable to their application. The rules include evidentiary provisions addressing qualification based on residence during the relevant period, receipt of specified government assistance, and marijuana-related arrests or convictions involving the applicant or specified family members. The rules also contain ownership requirements applicable to regulated marijuana businesses held by social equity licensees. Because those criteria have been amended over time, applicants should ensure they are using the current version of the rules and the current statutes rather than relying on older summaries of the program.

What mistakes should an applicant avoid?

• Do not assume that a state-level license category is available at a particular location without confirming the local jurisdiction’s rules and the site’s eligibility.
• Do not use an outdated ownership chart or incomplete financial-interest disclosure where the current MED application and rules require additional ownership or investment information.
• Do not assume that every owner and worker requires the same individual credential. Owner License, Employee License, and identification-badge requirements depend on the role and status addressed by the rules.
• Do not budget only for state fees, because local jurisdictions may impose separate fees and licensing requirements.

Are the Colorado rules subject to change?

Yes. In fact, the MED just concluded a rulemaking session in preparation for a rule change. We will keep you posted on these changes when they are finalized and published.

What is the bottom line?

A Colorado marijuana business must satisfy the state licensing framework and the requirements of the relevant local jurisdiction before operating. The applicable license type, ownership structure, individual-license requirements, fees, and local-site restrictions should be analyzed under the current MED rules and the current local code for the proposed premises. For Denver transactions, the social-equity exclusivity and transfer provisions remain applicable through a sunset date of July 1, 2027.

The post How to Acquire a Colorado Cannabis License appeared first on Harris Sliwoski LLP.

from Canna Law Blog™ https://ift.tt/z84pEQj
via IFTTT

Fast Buds breaks awards record at the 2026 Autoflower World Cup

Discover the strains that propelled Fast Buds to the winners circle at the 2026 Autoflower World Cup

The post Fast Buds breaks awards record at the 2026 Autoflower World Cup appeared first on Leafly.

from Leafly https://ift.tt/kaGlns3
via IFTTT